Sign In
Buy NKTR
$59.23
+0.670 (+1.14%)
At Close: Jun 03, 2026
SAN FRANCISCO , July 26, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter 2022 on Thursday, August 4, 2022, after the close of U.S.-ba
How to Find Penny Stocks to Buy in Summer 2022
03:30pm, Saturday, 16'th Jul 2022 PennyStocks
Use these tips to find penny stocks to buy this Summer
The post How to Find Penny Stocks to Buy in Summer 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
How to Find Penny Stocks to Buy in Summer 2022
11:30am, Saturday, 16'th Jul 2022
Use these tips to find penny stocks to buy this Summer The post How to Find Penny Stocks to Buy in Summer 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Catalyst (CPRX) Stock Jumps 10%: Will It Continue to Soar?
10:01am, Thursday, 14'th Jul 2022 Zacks Investment Research
Catalyst (CPRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in
Expert Ratings for Nektar Therapeutics
07:06pm, Tuesday, 31'st May 2022 Benzinga
Within the last quarter, Nektar Therapeutics (NASDAQ:NKTR) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
1
1
5
1
1
What to Know About Buying Penny Stocks on May 11th
12:30pm, Wednesday, 11'th May 2022 PennyStocks
Here's what you need to know about trading penny stocks today
The post What to Know About Buying Penny Stocks on May 11th appeared first on Penny Stocks to Buy, Picks, News and Information | PennyS
What to Know About Buying Penny Stocks on May 11th
08:30am, Wednesday, 11'th May 2022
Here's what you need to know about trading penny stocks today The post What to Know About Buying Penny Stocks on May 11th appeared first on Penny Stocks to Buy, Picks, News and Information | PennySt
Nektar's (NKTR) Q1 Earnings Top, Workforce Reduction on Track
02:07pm, Friday, 06'th May 2022 Zacks Investment Research
Nektar (NKTR) reports encouraging first-quarter 2022 results. The company remains on track with its restructuring plans following the discontinuation of bempeg development.
Nektar Therapeutics (NKTR) Reports Q1 Loss, Tops Revenue Estimates
09:55pm, Thursday, 05'th May 2022 Zacks Investment Research
Nektar (NKTR) delivered earnings and revenue surprises of 31.94% and 3.22%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Nektar Therapeutics (NKTR) Reports Q1 Loss, Tops Revenue Estimates
07:34pm, Thursday, 05'th May 2022
Nektar (NKTR) delivered earnings and revenue surprises of 31.94% and 3.22%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates
12:15pm, Wednesday, 04'th May 2022 Zacks Investment Research
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 32.35% and 9.90%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
07:02pm, Thursday, 28'th Apr 2022 Zacks Investment Research
Nektar (NKTR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bristol-Myers (BMY) to Post Q1 Earnings: Is a Beat in Store?
04:00pm, Wednesday, 27'th Apr 2022 Zacks Investment Research
Bristol-Myers (BMY) Q1 earnings might have gained from strong demand for Eliquis and incremental contribution from newer drugs. Operating expenses might have jumped on broader portfolio-related costs.
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Protagonist's Ulcerative Colitis Study Disappoints With Higher Dose Of PN-943
Protagonist Therapeutics
After Bristol Myers Cuts Ties, Nektar Implements Cost Restructuring
11:54am, Tuesday, 26'th Apr 2022
Nektar Therapeutics (NASDAQ: NKTR) announced a new strategic plan to prioritize key research and development efforts and cut 70% of its workforce, including several changes to its executive team.
